Geron Corporation
$ 1.14
3.64%
11 Jun - close price
- Market Cap 731,334,000 USD
- Current Price $ 1.14
- High / Low $ 1.22 / 1.08
- Stock P/E N/A
- Book Value 0.36
- EPS -0.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.27 %
- 52 Week High 2.01
- 52 Week Low 1.04
About
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.0049 | -0.0212 | -0.03 | -0.02 | -0.03 | -0.0356 | -0.04 | -0.1 | -0.09 | -0.09 | -0.08 | -0.09 |
| Estimated EPS | -0.024 | -0.028 | -0.03 | -0.03 | -0.0357 | -0.0464 | -0.08 | -0.1 | -0.1 | -0.1 | -0.1 | -0.08 |
| Surprise | 0.0191 | 0.0068 | 0 | 0.01 | 0.0057 | 0.0108 | 0.04 | 0 | 0.01 | 0.01 | 0.02 | -0.01 |
| Surprise Percentage | 79.5833% | 24.2857% | 0% | 33.3333% | 15.9664% | 23.2759% | 50% | 0% | 10% | 10% | 20% | -12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GERN
2026-06-09 18:39:16
Geron Corp has transitioned into a commercial-stage biotech after receiving FDA approval for its blood cancer drug imetelstat to treat lower-risk myelodysplastic syndromes (MDS) following positive Phase 3 data. The company's focus is now on the commercial launch, including pricing, reimbursement, and market access in the US, while also continuing to invest in clinical development to expand imetelstat into additional indications like myelofibrosis. Investors are closely watching initial sales metrics and future clinical and regulatory milestones.
2026-06-06 14:39:35
Geron's stock (GERN) tumbled over 10% pre-market after its fourth-quarter and full-year 2025 results showed total revenue and loss per share falling below analysts' estimates. Despite this, net product sales for its blood cancer therapy RYTELO reached $48 million in Q4, with sales and demand climbing, and the company projects RYTELO revenue between $220 million and $240 million for 2026. Retail sentiment on Stocktwits remained bullish even as the stock declined.
2026-06-05 12:39:36
Geron Corp shares are trading around the USD 1 mark on Nasdaq, with investors weighing recent pullbacks, short interest data, and valuation metrics. As of mid-May 2026, short interest saw a 7.3% decline, indicating a slight easing of bearish sentiment. Given Geron is a development-stage biotech, its valuation is driven by expectations of future clinical and regulatory milestones rather than traditional earnings multiples.
2026-06-03 19:09:04
This page provides a comprehensive resource for Geron Corp (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Key filings include the appointment of Harout Semerjian as the new CEO with details on his compensation and equity inducement, as well as various quarterly earnings and material event reports. The platform tracks 45 SEC filings for GERN, offering tools and insights for investors and traders.
2026-06-01 12:09:14
Geron (Nasdaq: GERN) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, where company management will host a fireside chat on Monday, June 8, 2026, at 8:40 a.m. ET in Miami, Florida. A live and archived audio webcast of the event will be available on Geron's website. The announcement highlights Geron's continuous engagement with investors, following recent updates on RYTELO® commercialization and Q1 2026 results.
2026-05-27 22:40:06
Analysts have slightly revised down Geron's price target due to more conservative assumptions regarding revenue growth, profit margins, and future P/E, though the intrinsic fair value estimate remains unchanged. Bullish analysts see this as a fine-tuning, while bearish analysts view it as a recognition that prior expectations might have been overly optimistic. Key drivers for Geron include an expanding patient pool due to an aging population, strong adoption of RYTELO, and potential pipeline expansion, though risks include reliance on a single drug and execution challenges in new launches.
